Clinical Trial Update: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated tislelizumab in combination with chemotherapy as first-line treatment for adults with inoperable, locally advanced or metastatic gastric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Chemotherapy (various regimens) (chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Gastric, or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2025-02-14